U.S. FDA Approves XARELTO ® (rivaroxaban) to Reduce the Risk of Major Cardiovascular Events in Patients with Chronic Coronary Artery Disease (CAD) or Peripheral Artery Disease (PAD)

Source: Johnson and Johnson - Category: Pharmaceuticals Source Type: news